



















subtype ratios as seen in *Nkx2.2*<sup>-/-</sup> mice, suggesting a function for *Nkx6.1* downstream of *Nkx2.2* (93). *Nkx6.1* is broadly expressed in the pancreatic epithelium from e9.0, is later expressed in endocrine progenitors, then subsequently becomes  $\beta$ -cell-restricted (93). Unlike *Nkx2.2* mutants, *Nkx6.1*-null mice specifically lose only the  $\beta$ -cell lineage (93). The  $\beta$ -cell loss in *Nkx6.1*-deficient mice could, however, also be secondary to the early endocrine to acinar cell fate switch caused by *Nkx6.1* abrogation in MPCs (62), thus illustrating the general limitation of studying specific gene functions in null mutant animals. The specific role of *Nkx6.1* in  $\beta$ -cell specification/differentiation remains to be defined and will require conditional gene inactivation in a temporally and spatially regulated manner.

The recent dissection of the role played by *Arx* in endocrine cell development has yielded insight into the mechanisms regulating the segregation of the  $\alpha$ - and  $\beta$ -cell lineages. *Arx* is expressed in a *Ngn3*-dependent fashion from e9.5 in the pancreas whereafter its expression becomes confined to  $\alpha$ - and PP-cells (94,95). Abrogation of *Arx* activity causes  $\alpha$ -cell deficiency while numbers of  $\beta$ - and  $\delta$ -cells are increased (94), revealing *Arx* to be both required for  $\alpha$ -cell fate acquisition and repression of  $\beta$ - and  $\delta$ -cell fate, the mirror opposite of the role of *Pax4* with which *Arx* is coexpressed during early endocrine differentiation. Concordantly, ectopic *Arx* expression in the endocrine precursors or mature  $\beta$ -cells expands  $\alpha$ - and PP-cell numbers at the expense of  $\beta$ -cells (95), showing *Arx* to be both necessary and sufficient to promote  $\alpha$ - and PP-lineage commitment. These findings are consistent with studies showing that *Pax4* and *Arx* mutually and directly inhibit one another's transcription at the promoter level (96). The observation that both  $\alpha$ - and  $\beta$ -cells in *Pax4; Arx* compound mutant mice are replaced by  $\delta$ -cells, which later initiate ectopic PP expression (96), has led to a refinement of the model by which *Pax4/Arx* govern islet cell subtype choices downstream of *Ngn3*. Namely, it has been proposed that when one of the two factors is activated in preference to the other in endocrine progenitors, *Arx* specifies  $\alpha$ -cell fate while *Pax4* first permits commitment toward a  $\beta$ -/ $\delta$ -cell fate by repressing *Arx* then subsequently driving a hypothetical bipotential  $\beta$ -/ $\delta$ -cell precursor cell toward a  $\beta$ -cell fate (96) (Fig. 3 Model A). This prevailing model is based on the assumption that two cells with different endocrine subtype identity arise from an intermediary progenitor downstream of *Ngn3*, which is in apparent contradiction to the recent observation that each *Ngn3*<sup>+</sup> cell only gives rise to one endocrine cell and is therefore unipotent (77). Reconciling this apparent contradiction, an alternative explanation for the observed phenotypes is that *Arx* and *Pax4* function to stabilize lineage decisions downstream of *Ngn3* rather than reallocating cells at the level of a hypothetical intermediate precursor cell (Fig. 3 Model B). Additional studies are clearly required to determine when and how endocrine subtype identity is established and stabilized during development.

Similar to *Arx* and *Pax4*, most recently, loss-of-function studies in both mouse (97) and zebrafish (98) have intriguingly hinted at a role for the transcription factor *Rfx6* in controlling endocrine cell subtype choice. *Rfx6*, which is activated by *Ngn3*, is expressed broadly throughout the epithelium of the mouse gut by e9.0 and within a subset of endocrine progenitor cells during the secondary transition, becoming restricted to islet cells by adulthood (97,98).

*Rfx6* exhibits a parallel expression pattern in zebrafish pancreas (98). Consistent with its endocrine expression, mice lacking *Rfx6* exhibit a loss of all mature endocrine cell types with the notable exception of the PP-cells, which unusually express the  $\beta$ -cell marker *Nkx6.1* (97). In zebrafish, *Rfx6* abrogation results in failure of the non- $\beta$ -cell endocrine lineages to differentiate from endocrine progenitors while the  $\beta$ -cells fail to coalesce into an islet (98). Future studies will be needed to determine the specific roles played by *Rfx6* in the transcription factor network orchestrating endocrine differentiation.

#### ISLET FORMATION AND $\beta$ -CELL MATURATION

As birth nears, the exocrine pancreas grows rapidly, primarily through mitotic expansion of differentiated acinar cells. Meanwhile, from e16.5 onwards, the endocrine cells coalesce into polyclonal clusters to form functional islets that, in the mouse, comprise a central core of  $\beta$ -cells and an outer mantle composed of the other four endocrine cell types. Disrupted islet cytoarchitecture following  $\beta$ -cell-specific deletion of cadherins or neural cell adhesion molecule has revealed a requirement for cell adhesion molecules in  $\beta$ -cell- $\beta$ -cell adhesion during islet formation (99,100). In addition, *in vitro* evidence (101) supports a role for matrix metalloproteinase enzymes in facilitating endocrine cell migration via extracellular matrix degradation. However, this hypothesis has not been borne out *in vivo* (102).

During the early postnatal period, the  $\beta$ -cells acquire the ability to regulate insulin secretion in response to glucose (103), requiring the expression of the glucose transporter *Glut2* and prohormone convertase *PC1/3* to cleave proinsulin to active insulin. The recent characterization of the roles played by the transcription factors *MafA* and *MafB* in pancreas development has offered insight into the mechanisms governing  $\beta$ -cell terminal differentiation. *MafA*, which was initially identified as a  $\beta$ -cell-specific activator of insulin transcription (reviewed in [104]), is exclusively expressed in insulin<sup>+</sup> cells from e13.5 onward (105). In contrast, *MafB* is expressed in both insulin<sup>+</sup> and glucagon<sup>+</sup> cells by e12.5 but becomes restricted postnatally to  $\alpha$ -cells (106). Thus, maturing  $\beta$ -cells undergo a developmental *MafB*→*MafA* switch (107). Apparently conflicting with its expression in immature insulin<sup>+</sup> cells, *MafA* function is dispensable for  $\beta$ -cell development, most likely because of functional compensation by *MafB* (108). However, deletion of *MafB* reduces numbers of insulin<sup>+</sup> and glucagon<sup>+</sup> cells and delays the development of insulin<sup>+</sup> cells until the onset of *MafA* expression (109). Loss of *MafB* is associated with downregulation of factors required for  $\beta$ -cell maturation and function such as *Pdx1*, *MafA*, *Nkx6.1*, and *Glut2*. *MafB* is thus crucially required for the terminal differentiation of both  $\alpha$ - and  $\beta$ -cells by acting as a master activator of hormone gene transcription and key regulators of  $\beta$ -cell differentiation and function.

Serving as a potent example of individual transcription factors exhibiting multiple roles during pancreatic development, conditional deletion of *Isl1* has recently unmasked a crucial requirement for this transcription factor in endocrine cell maturation (110). Ablation of *Isl1* immediately prior to the secondary transition results in a severe reduction in the number of mature endocrine cells prior to the eventual loss of endocrine cell mass contributed by the changes in cell proliferation and survival (110). Paralleling the multiple roles played by *Isl1* in pancreatic organogenesis, recent studies have also uncovered

additional, later roles for Ngn3 and its downstream target, NeuroD1, in the acquisition and maintenance of the terminally differentiated, fully functional  $\beta$ -cell phenotype (75,111). Future work will undoubtedly focus on further elucidating the roles of Isl1 and other endocrine differentiation factors in  $\beta$ -cell maintenance and function as the requisite genetic tools become available.

#### FUTURE PERSPECTIVES

Despite the wealth of knowledge we have amassed to date, many questions in the field of pancreas and  $\beta$ -cell development remain unanswered, as this review has sought to illustrate. It is only relatively recently, for example, that evolving transgenic mouse technology has provided insight into the roles of transcription factors such as Ptf1a and Sox17 in allocating pancreatic fate at the expense of other endodermally derived organs. The inability of any single gene deletion to prevent formation of the early pancreatic anlage hints at the complexity of the transcriptional network governing this process and the involvement of as yet unidentified players, which further work will undoubtedly unmask. How known transcriptional regulators interact with one another and with extraneous signaling pathways is also ripe for future examination, whether in the control of pancreatic specification, growth, or cytodifferentiation.

Outstanding among current questions in the field is the issue of multipotency of individual progenitors at single-cell resolution. This area of investigation would greatly benefit from the development of a culture system in which organ development can be initiated from single cells in vitro, as recently established for cells in the intestinal crypts (112). Another still understudied area is the question of whether or how the physical location of cells in the developing pancreas bestows lineage-restriction upon progenitors. Open questions include whether all ductal cells in the secondary transition progenitor cords function as progenitor cells; whether such progenitors are homogeneously or heterogeneously lineage-restricted; and if the latter, the factor(s) governing progenitor commitment or differentiation into ductal, endocrine, or acinar lineages. Finally, as illustrated in this review, we still know very little about when and how the five different endocrine cell subtypes are specified during development. It is anticipated that much effort will be expended in the future with the goal of answering some of these questions. It is hoped that acquiring more comprehensive insight into the processes governing  $\beta$ -cell neogenesis in vivo will enable the in vitro generation of unlimited quantities of functional insulin-producing cells for the successful management and eventual cure of diabetes.

#### ACKNOWLEDGMENTS

This work is supported by grants from the Juvenile Diabetes Research Foundation, the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases, and The NIH  $\beta$  Cell Biology Consortium (BCBC).

No potential conflicts of interest relevant to this article were reported.

P.A.S. researched data and wrote the manuscript. M.S. reviewed and edited the manuscript and contributed to discussion.

We thank our colleagues, whose work is cited here, for their contributions and apologize to all of those whose

references were omitted due to space constraints. We are also grateful to members of the Sander laboratory for constructive comments on the manuscript.

#### REFERENCES

1. D'Amour KA, Bang AG, Eliazar S, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. *Nat Biotechnol* 2006;24:1392–1401
2. Pictet RL, Clark WR, Williams RH, Rutter WJ. An ultrastructural analysis of the developing embryonic pancreas. *Dev Biol* 1972;29:436–467
3. Hebrok M, Kim SK, St Jacques B, McMahon AP, Melton DA. Regulation of pancreas development by hedgehog signaling. *Development* 2000;127:4905–4913
4. Kim SK, Hebrok M, Melton DA. Notochord to endoderm signaling is required for pancreas development. *Development* 1997;124:4243–4252
5. Kim SK, Melton DA. Pancreas development is promoted by cyclopamine, a hedgehog signaling inhibitor. *Proc Natl Acad Sci USA* 1998;95:13036–13041
6. Hebrok M, Kim SK, Melton DA. Notochord repression of endodermal Sonic hedgehog permits pancreas development. *Genes Dev* 1998;12:1705–1713
7. Wandzioch E, Zaret KS. Dynamic signaling network for the specification of embryonic pancreas and liver progenitors. *Science* 2009;324:1707–1710
8. Stafford D, Prince VE. Retinoic acid signaling is required for a critical early step in zebrafish pancreatic development. *Curr Biol* 2002;12:1215–1220
9. Chen Y, Pan FC, Brandes N, Afelik S, Sölter M, Pieler T. Retinoic acid signaling is essential for pancreas development and promotes endocrine at the expense of exocrine cell differentiation in *Xenopus*. *Dev Biol* 2004;271:144–160
10. Martín M, Gallego-Llamas J, Ribes V, et al. Dorsal pancreas agenesis in retinoic acid-deficient *Raldh2* mutant mice. *Dev Biol* 2005;284:399–411
11. Molotkov A, Molotkova N, Duester G. Retinoic acid generated by *Raldh2* in mesoderm is required for mouse dorsal endodermal pancreas development. *Dev Dyn* 2005;232:950–957
12. Lammert E, Cleaver O, Melton D. Induction of pancreatic differentiation by signals from blood vessels. *Science* 2001;294:564–567
13. Yoshitomi H, Zaret KS. Endothelial cell interactions initiate dorsal pancreas development by selectively inducing the transcription factor Ptf1a. *Development* 2004;131:807–817
14. Jacquemin P, Yoshitomi H, Kashima Y, Rousseau GG, Lemaigre FP, Zaret KS. An endothelial-mesenchymal relay pathway regulates early phases of pancreas development. *Dev Biol* 2006;290:189–199
15. Kinkel MD, Eames SC, Alonzo MR, Prince VE. *Cdx4* is required in the endoderm to localize the pancreas and limit beta-cell number. *Development* 2008;135:919–929
16. Asayesh A, Sharpe J, Watson RP, et al. Spleen versus pancreas: strict control of organ interrelationship revealed by analyses of *Bapx1*<sup>-/-</sup> mice. *Genes Dev* 2006;20:2208–2213
17. Bort R, Martinez-Barbera JP, Beddington RS, Zaret KS. Hex homeobox gene-dependent tissue positioning is required for organogenesis of the ventral pancreas. *Development* 2004;131:797–806
18. Guz Y, Montminy MR, Stein R, et al. Expression of murine STF-1, a putative insulin gene transcription factor, in beta cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. *Development* 1995;121:11–18
19. Ahlgren U, Jonsson J, Edlund H. The morphogenesis of the pancreatic mesenchyme is uncoupled from that of the pancreatic epithelium in *IPF1*/*PDX1*-deficient mice. *Development* 1996;122:1409–1416
20. Offield MF, Jetton TL, Labosky PA, et al. *PDX-1* is required for pancreatic outgrowth and differentiation of the rostral duodenum. *Development* 1996;122:983–995
21. Kawaguchi Y, Cooper B, Gannon M, Ray M, MacDonald RJ, Wright CV. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. *Nat Genet* 2002;32:128–134
22. Krapp A, Knöfler M, Frutiger S, Hughes GJ, Hagenbüchle O, Wellauer PK. The p48 DNA-binding subunit of transcription factor PTF1 is a new exocrine pancreas-specific basic helix-loop-helix protein. *EMBO J* 1996;15:4317–4329
23. Krapp A, Knöfler M, Ledermann B, et al. The bHLH protein PTF1-p48 is essential for the formation of the exocrine and the correct spatial organization of the endocrine pancreas. *Genes Dev* 1998;12:3752–3763
24. Burlison JS, Long Q, Fujitani Y, Wright CV, Magnuson MA. *Pdx-1* and *Ptf1a* concurrently determine fate specification of pancreatic multipotent progenitor cells. *Dev Biol* 2008;316:74–86

25. Afelik S, Chen Y, Pieler T. Combined ectopic expression of Pdx1 and Ptf1a/p48 results in the stable conversion of posterior endoderm into endocrine and exocrine pancreatic tissue. *Genes Dev* 2006;20:1441–1446
26. Spence JR, Lange AW, Lin SC, et al. Sox17 regulates organ lineage segregation of ventral foregut progenitor cells. *Dev Cell* 2009;17:62–74
27. Harrison KA, Thaler J, Pfaff SL, Gu H, Kehrl JH. Pancreas dorsal lobe agenesis and abnormal islets of Langerhans in Hlx9-deficient mice. *Nat Genet* 1999;23:71–75
28. Li H, Arber S, Jessell TM, Edlund H. Selective agenesis of the dorsal pancreas in mice lacking homeobox gene Hlx9. *Nat Genet* 1999;23:67–70
29. Murtaugh LC. Pancreas and beta-cell development: from the actual to the possible. *Development* 2007;134:427–438
30. Wu KL, Gannon M, Peshavaria M, et al. Hepatocyte nuclear factor 3beta is involved in pancreatic beta-cell-specific transcription of the pdx-1 gene. *Mol Cell Biol* 1997;17:6002–6013
31. Jacquemin P, Lemaigre FP, Rousseau GG. The Onecut transcription factor HNF-6 (OC-1) is required for timely specification of the pancreas and acts upstream of Pdx-1 in the specification cascade. *Dev Biol* 2003;258:105–116
32. Lee CS, Sund NJ, Behr R, Herrera PL, Kaestner KH. Foxa2 is required for the differentiation of pancreatic alpha-cells. *Dev Biol* 2005;278:484–495
33. Jacquemin P, Durvieux SM, Jensen J, et al. Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine cell differentiation and controls expression of the proendocrine gene ngn3. *Mol Cell Biol* 2000;20:4445–4454
34. Haumaitre C, Barbacci E, Jenny M, Ott MO, Gradwohl G, Cereghini S. Lack of TCF2/vHNF1 in mice leads to pancreas agenesis. *Proc Natl Acad Sci USA* 2005;102:1490–1495
35. Kumar M, Melton D. Pancreas specification: a budding question. *Curr Opin Genet Dev* 2003;13:401–407
36. Kesavan G, Sand FW, Greiner TU, et al. Cdc42-mediated tubulogenesis controls cell specification. *Cell* 2009;139:791–801
37. Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. *Development* 2002;129:2447–2457
38. Chiang MK, Melton DA. Single-cell transcript analysis of pancreas development. *Dev Cell* 2003;4:383–393
39. Stanger BZ, Tanaka AJ, Melton DA. Organ size is limited by the number of embryonic progenitor cells in the pancreas but not the liver. *Nature* 2007;445:886–891
40. Golosow N, Grobstein C. Epitheliomesenchymal interaction in pancreatic morphogenesis. *Dev Biol* 1962;4:242–255
41. Wessells NK, Cohen JH. Early pancreas organogenesis: morphogenesis, tissue interactions, and mass effects. *Dev Biol* 1967;15:237–270
42. Ahlgren U, Pfaff SL, Jessell TM, Edlund T, Edlund H. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. *Nature* 1997;385:257–260
43. Bhushan A, Itoh N, Kato S, et al. Fgf10 is essential for maintaining the proliferative capacity of epithelial progenitor cells during early pancreatic organogenesis. *Development* 2001;128:5109–5117
44. Pulkkinen MA, Spencer-Dene B, Dickson C, Otonkoski T. The IIIb isoform of fibroblast growth factor receptor 2 is required for proper growth and branching of pancreatic ductal epithelium but not for differentiation of exocrine or endocrine cells. *Mech Dev* 2003;120:167–175
45. Norgaard GA, Jensen JN, Jensen J. FGF10 signaling maintains the pancreatic progenitor cell state revealing a novel role of Notch in organ development. *Dev Biol* 2003;264:323–338
46. Jonckheere N, Mayes E, Shih HP, et al. Analysis of mPygo2 mutant mice suggests a requirement for mesenchymal Wnt signaling in pancreatic growth and differentiation. *Dev Biol* 2008;318:224–235
47. Ahnfelt-Rønne J, Ravassard P, Pardanaud-Glavieux C, Scharfmann R, Serup P. Mesenchymal bone morphogenetic protein signaling is required for normal pancreas development. *Diabetes* 2010;59:1948–1956
48. Jessen S, Gu B, Dai X. Pygopus and the Wnt signaling pathway: a diverse set of connections. *Bioessays* 2008;30:448–456
49. Georgia S, Soliz R, Li M, Zhang P, Bhushan A. p57 and Hes1 coordinate cell cycle exit with self-renewal of pancreatic progenitors. *Dev Biol* 2006;298:22–31
50. Jensen J, Pedersen EE, Galante P, et al. Control of endodermal endocrine development by Hes-1. *Nat Genet* 2000;24:36–44
51. Apelqvist A, Li H, Sommer L, et al. Notch signalling controls pancreatic cell differentiation. *Nature* 1999;400:877–881
52. Fujikura J, Hosoda K, Iwakura H, et al. Notch/Rbp-j signaling prevents premature endocrine and ductal cell differentiation in the pancreas. *Cell Metab* 2006;3:59–65
53. Lee JC, Smith SB, Watada H, et al. Regulation of the pancreatic pro-endocrine gene neurogenin3. *Diabetes* 2001;50:928–936
54. Esni F, Ghosh B, Biankin AV, et al. Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. *Development* 2004;131:4213–4224
55. Seymour PA, Freude KK, Tran MN, et al. SOX9 is required for maintenance of the pancreatic progenitor cell pool. *Proc Natl Acad Sci USA* 2007;104:1865–1870
56. Murtaugh LC, Law AC, Dor Y, Melton DA. Beta-catenin is essential for pancreatic acinar but not islet development. *Development* 2005;132:4663–4674
57. Papadopoulou S, Edlund H. Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function. *Diabetes* 2005;54:2844–2851
58. Heiser PW, Lau J, Taketo MM, Herrera PL, Hebrok M. Stabilization of beta-catenin impacts pancreas growth. *Development* 2006;133:2023–2032
59. Heller RS, Klein T, Ling Z, et al. Expression of Wnt, Frizzled, sFRP, and DKK genes in adult human pancreas. *Gene Expr* 2003;11:141–147
60. Zhou Q, Law AC, Rajagopal J, Anderson WJ, Gray PA, Melton DA. A multipotent progenitor domain guides pancreatic organogenesis. *Dev Cell* 2007;13:103–114
61. Solar M, Cardalda C, Houbracken I, et al. Pancreatic exocrine duct cells give rise to insulin-producing beta cells during embryogenesis but not after birth. *Dev Cell* 2009;17:849–860
62. Schaffer AE, Freude KK, Nelson SB, Sander M. Nkx6 transcription factors and Ptf1a function as antagonistic lineage determinants in multipotent pancreatic progenitors. *Dev Cell* 2010;18:1022–1029
63. Seymour PA, Freude KK, Dubois CL, Shih HP, Patel NA, Sander M. A dosage-dependent requirement for Sox9 in pancreatic endocrine cell formation. *Dev Biol* 2008;323:19–30
64. Kopinke D, Murtaugh LC. Exocrine-to-endocrine differentiation is detectable only prior to birth in the uninjured mouse pancreas. *BMC Dev Biol* 2010;10:38
65. Rutter WJ, Pictet RL, Harding JD, Chirgwin JM, MacDonald RJ, Przybyla AE. An analysis of pancreatic development: role of mesenchymal factor and other extracellular factors. *Symp Soc Dev Biol* 1978;35:205–227
66. Gittes GK, Galante PE, Hanahan D, Rutter WJ, Debase HT. Lineage-specific morphogenesis in the developing pancreas: role of mesenchymal factors. *Development* 1996;122:439–447
67. Duvillé B, Attali M, Boumacer A, Ravassard P, Basmaciogullari A, Scharfmann R. The mesenchyme controls the timing of pancreatic beta-cell differentiation. *Diabetes* 2006;55:582–589
68. Miralles F, Czernichow P, Scharfmann R. Follistatin regulates the relative proportions of endocrine versus exocrine tissue during pancreatic development. *Development* 1998;125:1017–1024
69. Crisera CA, Kadison AS, Breslow GD, Maldonado TS, Longaker MT, Gittes GK. Expression and role of laminin-1 in mouse pancreatic organogenesis. *Diabetes* 2000;49:936–944
70. Li Z, Manna P, Kobayashi H, et al. Multifaceted pancreatic mesenchymal control of epithelial lineage selection. *Dev Biol* 2004;269:252–263
71. Miralles F, Czernichow P, Ozaki K, Itoh N, Scharfmann R. Signaling through fibroblast growth factor receptor 2b plays a key role in the development of the exocrine pancreas. *Proc Natl Acad Sci USA* 1999;96:6267–6272
72. Wells JM, Esni F, Boivin GP, et al. Wnt/beta-catenin signaling is required for development of the exocrine pancreas. *BMC Dev Biol* 2007;7:4
73. Dessimoz J, Bonnard C, Huelsken J, Grapin-Botton A. Pancreas-specific deletion of beta-catenin reveals Wnt-dependent and Wnt-independent functions during development. *Curr Biol* 2005;15:1677–1683
74. Gradwohl G, Dierich A, LeMeur M, Guillemot F. neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. *Proc Natl Acad Sci USA* 2000;97:1607–1611
75. Wang S, Jensen JN, Seymour PA, et al. Sustained Neurog3 expression in hormone-expressing islet cells is required for endocrine maturation and function. *Proc Natl Acad Sci USA* 2009;106:9715–9720
76. Wang S, Yan J, Anderson DA, et al. Neurog3 gene dosage regulates allocation of endocrine and exocrine cell fates in the developing mouse pancreas. *Dev Biol* 2010;339:26–37
77. Desgraz R, Herrera PL. Pancreatic neurogenin 3-expressing cells are unipotent islet precursors. *Development* 2009;136:3567–3574
78. Mellitzer G, Beucher A, Lobstein V, et al. Loss of enteroendocrine cells in mice alters lipid absorption and glucose homeostasis and impairs post-natal survival. *J Clin Invest* 2010;120:1708–1721
79. Jenny M, Uhl C, Roche C, et al. Neurogenin3 is differentially required for endocrine cell fate specification in the intestinal and gastric epithelium. *EMBO J* 2002;21:6338–6347
80. Lee CS, Perreault N, Brestelli JE, Kaestner KH. Neurogenin 3 is essential for the proper specification of gastric enteroendocrine cells and the maintenance of gastric epithelial cell identity. *Genes Dev* 2002;16:1488–1497

81. Wang J, Cortina G, Wu SV, et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. *N Engl J Med* 2006;355:270–280
82. Johansson KA, Dursun U, Jordan N, et al. Temporal control of neurogenin3 activity in pancreas progenitors reveals competence windows for the generation of different endocrine cell types. *Dev Cell* 2007;12:457–465
83. Mellitzer G, Bonn  S, Luco RF, et al. IA1 is NGN3-dependent and essential for differentiation of the endocrine pancreas. *EMBO J* 2006;25:1344–1352
84. Gierl MS, Karoulias N, Wende H, Strehle M, Birchmeier C. The zinc-finger factor *Insm1* (IA-1) is essential for the development of pancreatic beta cells and intestinal endocrine cells. *Genes Dev* 2006;20:2465–2478
85. Breslin MB, Zhu M, Notkins AL, Lan MS. Neuroendocrine differentiation factor, IA-1, is a transcriptional repressor and contains a specific DNA-binding domain: identification of consensus IA-1 binding sequence. *Nucleic Acids Res* 2002;30:1038–1045
86. Naya FJ, Huang HP, Qiu Y, et al. Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in *BETA2/neuroD*-deficient mice. *Genes Dev* 1997;11:2323–2334
87. Sussel L, Kalamaras J, Hartigan-O'Connor DJ, et al. Mice lacking the homeodomain transcription factor *Nkx2.2* have diabetes due to arrested differentiation of pancreatic beta cells. *Development* 1998;125:2213–2221
88. Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P. The *Pax4* gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. *Nature* 1997;386:399–402
89. Prado CL, Pugh-Bernard AE, Elghazi L, Sosa-Pineda B, Sussel L. Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. *Proc Natl Acad Sci USA* 2004;101:2924–2929
90. Heller RS, Jenny M, Collombat P, et al. Genetic determinants of pancreatic epsilon-cell development. *Dev Biol* 2005;286:217–224
91. Collombat P, Xu X, Ravassard P, et al. The ectopic expression of *Pax4* in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells. *Cell* 2009;138:449–462
92. Watada H, Mirmira RG, Leung J, German MS. Transcriptional and translational regulation of beta-cell differentiation factor *Nkx6.1*. *J Biol Chem* 2000;275:34224–34230
93. Sander M, Sussel L, Connors J, et al. Homeobox gene *Nkx6.1* lies downstream of *Nkx2.2* in the major pathway of beta-cell formation in the pancreas. *Development* 2000;127:5533–5540
94. Collombat P, Mansouri A, Hecksher-Sorensen J, et al. Opposing actions of *Arx* and *Pax4* in endocrine pancreas development. *Genes Dev* 2003;17:2591–2603
95. Collombat P, Hecksher-Sorensen J, Krull J, et al. Embryonic endocrine pancreas and mature beta cells acquire alpha and PP cell phenotypes upon *Arx* misexpression. *J Clin Invest* 2007;117:961–970
96. Collombat P, Hecksher-Sorensen J, Broccoli V, et al. The simultaneous loss of *Arx* and *Pax4* genes promotes a somatostatin-producing cell fate specification at the expense of the alpha- and beta-cell lineages in the mouse endocrine pancreas. *Development* 2005;132:2969–2980
97. Smith SB, Qu HQ, Taleb N, et al. *Rfx6* directs islet formation and insulin production in mice and humans. *Nature* 2010;463:775–780
98. Soyer J, Flasse L, Raffelsberger W, et al. *Rfx6* is an *Ngn3*-dependent winged helix transcription factor required for pancreatic islet cell development. *Development* 2010;137:203–212
99. Dahl U, Sjodin A, Semb H. Cadherins regulate aggregation of pancreatic beta-cells in vivo. *Development* 1996;122:2895–2902
100. Esni F, T ljedal IB, Perl AK, Cremer H, Christofori G, Semb H. Neural cell adhesion molecule (N-CAM) is required for cell type segregation and normal ultrastructure in pancreatic islets. *J Cell Biol* 1999;144:325–337
101. Miralles F, Battelino T, Czernichow P, Scharfmann R. TGF-beta plays a key role in morphogenesis of the pancreatic islets of Langerhans by controlling the activity of the matrix metalloproteinase MMP-2. *J Cell Biol* 1998;143:827–836
102. Perez SE, Cano DA, Dao-Pick T, Rougier JP, Werb Z, Hebrok M. Matrix metalloproteinases 2 and 9 are dispensable for pancreatic islet formation and function in vivo. *Diabetes* 2005;54:694–701
103. Rozzo A, Meneghel-Rozzo T, Delakorda SL, Yang SB, Rupnik M. Exocytosis of insulin: in vivo maturation of mouse endocrine pancreas. *Ann N Y Acad Sci* 2009;1152:53–62
104. Oliver-Krasinski JM, Stoffers DA. On the origin of the beta cell. *Genes Dev* 2008;22:1998–2021
105. Matsuoka TA, Artner I, Henderson E, Means A, Sander M, Stein R. The *MafA* transcription factor appears to be responsible for tissue-specific expression of insulin. *Proc Natl Acad Sci USA* 2004;101:2930–2933
106. Artner I, Le Lay J, Hang Y, et al. *MafB*: an activator of the glucagon gene expressed in developing islet alpha- and beta-cells. *Diabetes* 2006;55:297–304
107. Nishimura W, Kondo T, Salameh T, et al. A switch from *MafB* to *MafA* expression accompanies differentiation to pancreatic beta-cells. *Dev Biol* 2006;293:526–539
108. Zhang C, Moriguchi T, Kajihara M, et al. *MafA* is a key regulator of glucose-stimulated insulin secretion. *Mol Cell Biol* 2005;25:4969–4976
109. Artner I, Bianchi B, Raum JC, et al. *MafB* is required for islet beta cell maturation. *Proc Natl Acad Sci USA* 2007;104:3853–3858
110. Du A, Hunter CS, Murray J, et al. *Islet-1* is required for the maturation, proliferation, and survival of the endocrine pancreas. *Diabetes* 2009;58:2059–2069
111. Gu C, Stein GH, Pan N, et al. Pancreatic beta cells require *NeuroD* to achieve and maintain functional maturity. *Cell Metab* 2010;11:298–310
112. Sato T, Vries RG, Snippet HJ, et al. Single *Lgr5* stem cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature* 2009;459:262–265
113. Kanai-Azuma M, Kanai Y, Gad JM, et al. Depletion of definitive gut endoderm in *Sox17*-null mutant mice. *Development* 2002;129:2367–2379
114. Monaghan AP, Kaestner KH, Grau E, Sch tz G. Postimplantation expression patterns indicate a role for the mouse forkhead/HNF-3 alpha, beta and gamma genes in determination of the definitive endoderm, chordamesoderm and neuroectoderm. *Development* 1993;119:567–578
115. Cockell M, Stolarczyk D, Frutiger S, Hughes GJ, Hagenb chle O, Wellauer PK. Binding sites for hepatocyte nuclear factor 3 beta or 3 gamma and pancreas transcription factor 1 are required for efficient expression of the gene encoding pancreatic alpha-amylase. *Mol Cell Biol* 1995;15:1933–1941
116. Ang SL, Rossant J. HNF-3 beta is essential for node and notochord formation in mouse development. *Cell* 1994;78:561–574
117. Weinstein DC, Ruiz i Altaba A, Chen WS, et al. The winged-helix transcription factor HNF-3 beta is required for notochord development in the mouse embryo. *Cell* 1994;78:575–588
118. Sund NJ, Vatamaniuk MZ, Casey M, et al. Tissue-specific deletion of *Foxa2* in pancreatic beta cells results in hyperinsulinemic hypoglycemia. *Genes Dev* 2001;15:1706–1715
119. Landry C, Clotman F, Hioki T, et al. HNF-6 is expressed in endoderm derivatives and nervous system of the mouse embryo and participates to the cross-regulatory network of liver-enriched transcription factors. *Dev Biol* 1997;192:247–257
120. Rausa F, Samadani U, Ye H, et al. The cut-homeodomain transcriptional activator HNF-6 is coexpressed with its target gene HNF-3 beta in the developing murine liver and pancreas. *Dev Biol* 1997;192:228–246
121. Maestro MA, Boj SF, Luco RF, et al. *Hnf6* and *Tcf2* (*MODY5*) are linked in a gene network operating in a precursor cell domain of the embryonic pancreas. *Hum Mol Genet* 2003;12:3307–3314
122. Johnson JD, Ahmed NT, Luciani DS, et al. Increased islet apoptosis in *Pdx1*<sup>+/-</sup> mice. *J Clin Invest* 2003;111:1147–1160
123. Fukuda A, Kawaguchi Y, Furuyama K, et al. Ectopic pancreas formation in *Hes1*-knockout mice reveals plasticity of endodermal progenitors of the gut, bile duct, and pancreas. *J Clin Invest* 2006;116:1484–1493
124. Lynn FC, Smith SB, Wilson ME, Yang KY, Nekrep N, German MS. *Sox9* coordinates a transcriptional network in pancreatic progenitor cells. *Proc Natl Acad Sci USA* 2007;104:10500–10505
125. Henseleit KD, Nelson SB, Kuhlbrodt K, Hennings JC, Ericson J, Sander M. *NKX6* transcription factor activity is required for alpha- and beta-cell development in the pancreas. *Development* 2005;132:3139–3149
126. Nelson SB, Schaffer AE, Sander M. The transcription factors *Nkx6.1* and *Nkx6.2* possess equivalent activities in promoting beta-cell fate specification in *Pdx1*<sup>+</sup> pancreatic progenitor cells. *Development* 2007;134:2491–2500